Think

Search This Blog

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

June 10, 2021

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

BY PAM BELLUCK AND REBECCA ROBBINS | NYTimes Health | Disclosure

Get link
Facebook
Twitter
Pinterest
Email
Other Apps

Comments

A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says

Results of a large clinical trial found the treatment did not work any better than a placebo. Pam Belluck | NYTimes Health | Disclosure

Hospitals Must Get Written Patient Consent for Pelvic Exams, H.H.S. Says

In a letter to teaching hospitals, the federal health agency said that institutions could lose Medicare funding if they didn’t comply. Emma Goldberg | NYTimes Health | Disclosure

Sleep Apnea Reduced in People Who Took Weight-Loss Drug, Eli Lilly Reports

The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. Gina Kolata | NYTimes Health | Disclosure

Many U.S. virus cases go uncounted. Are there better ways to track the pandemic?

BY EMILY ANTHES | NYTimes Health | Disclosure

Mental Health and Substance Use Disorders Often Go Untreated for Parents on Medicaid

Among those with substance use disorders who have been referred to child welfare, less than half received medication or counseling. Emily Baumgaertner | NYTimes Health | Disclosure

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug

Comments

Post a Comment